Caren Deardorf Net Worth

The estimated Net Worth of Caren Deardorf is at least $740 Thousand dollars as of 16 September 2021. Caren Deardorf owns over 6,238 units of Crinetics Pharmaceuticals Inc stock worth over $698,284 and over the last 3 years Caren sold CRNX stock worth over $41,982.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Caren Deardorf CRNX stock SEC Form 4 insiders trading

Caren has made over 1 trades of the Crinetics Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Caren sold 6,238 units of CRNX stock worth $41,982 on 16 September 2021.

The largest trade Caren's ever made was selling 6,238 units of Crinetics Pharmaceuticals Inc stock on 16 September 2021 worth over $41,982. On average, Caren trades about 520 units every 0 days since 2021. As of 16 September 2021 Caren still owns at least 13,762 units of Crinetics Pharmaceuticals Inc stock.

You can see the complete history of Caren Deardorf stock trades at the bottom of the page.

What's Caren Deardorf's mailing address?

Caren's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO, CA, 92121.

Insiders trading at Crinetics Pharmaceuticals Inc

Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen, and Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.

What does Crinetics Pharmaceuticals Inc do?

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.

Complete history of Caren Deardorf stock trades at Magenta Therapeutics Inc and Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc executives and stock owners

Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• R. Scott Struthers,
  President, Chief Executive Officer, Director
• Alan Krasner,
  Chief Medical Officer
• Marc Wilson,
  Chief Financial Officer
• Dr. R. Scott Struthers Ph.D.,
  Founder, Pres, CEO & Director
• Dr. Ajay Madan DABT, Ph.D., D.A.B.T.,
  Chief Devel. Officer
• Marc J. C. Wilson,
  CFO & Sec.
• Stephanie Okey,
  Independent Director
• Wendall Wierenga,
  Independent Chairman of the Board
• Matthew Fust,
  Independent Director
• Jeff E. Knight,
  Chief Operating Officer
• Stephen Kaldor,
  Independent Director
• Weston Nichols,
  Independent Director
• Peter Trainer,
  Vice President - Clinical Endocrinology
• Camille Bedrosian,
  Independent Director
• Adriana Cabre,
  Vice President of Human Resources
• Ajay Madan,
  Chief Development Officer
• Chris Robillard M.B.A.,
  Chief Bus. Officer
• James Hassard,
  Chief Commercial Officer
• Dr. Alan S. Krasner M.D.,
  Chief Medical Officer
• Adriana Cabre M.B.A.,
  Chief HR Officer
• Kevin Capps,
  Head of Intellectual Property
• Dr. Alan S. Krasner,
  Chief Medical Officer
• Garlan Adams,
  Gen. Counsel
• Dr. Stephen F. Betz Ph.D.,
  Founder & Chief Scientific Officer
• Dr. Yun-Fei Zhu,
  Founder & VP of Chemistry
• Jeff E. Knight,
  Chief Operating Officer
• Advisors Llcperceptive Life...,
  
• Capital Viii, Llc Vivo Capi...,
  
• Venture Capital V, L.P.Vers...,
  
• Capital Viii, Llc Vivo Capi...,
  
• Venture Capital V, L.P.Vers...,
  
• Capital Viii, Llc Vivo Capi...,
  
• James Hassard,
  Chief Commercial Officer
• Jack Nielsen,
  Director
• Coelho Rogerio Vivaldi,
  
• Dana Pizzuti,
  Chief Med and Dev Officer
• Stephen F. Betz,
  Chief Scientific Officer
• Caren Deardorf,